These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 27636933)

  • 1. [Role of polymorphic markers for the genes of hemostasis and platelet receptors in liver fibrosis progression in patients with chronic hepatitis C].
    Starostina EE; Samokhodskaya LM; Rozina TP; Krasnova TN; Yarovaya EB; Mukhin NA
    Ter Arkh; 2016; 88(8):93-98. PubMed ID: 27636933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mathematic Model for Prediction of Liver Fibrosis Progression Rate in Patients with Chronic Hepatitis C Based on Combination of Genomic Markers].
    Samokhodskaia LM; Starostina EE; Yarovaya EB; Krasnova TN; Mukhin NA; Tkachuk VA; Sadovnichy VA
    Vestn Ross Akad Med Nauk; 2015; (6):651-61. PubMed ID: 27093792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence of thrombophilic mutations of FV Leiden, prothrombin G20210A and PAl-1 4G/5G and their combinations in a group of 1450 healthy middle-aged individuals in the Prague and Central Bohemian regions (results of FRET real-time PCR assay)].
    Kvasnicka J; Hájková J; Bobcíková P; Kvasnicka T; Dusková D; Poletínová S; Kieferová V
    Cas Lek Cesk; 2012; 151(2):76-82. PubMed ID: 22515013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of features of the course of chronic hepatitis C using Bayesian networks.
    Samokhodskaya LM; Starostina EE; Sulimov AV; Krasnova ТN; Rosina TP; Avdeev VG; Savkin IA; Sulimov VB; Mukhin NA; Tkachuk VA; Sadovnichii VA
    Ter Arkh; 2019 Mar; 91(2):32-39. PubMed ID: 31094169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence variations in the FII, FV, F13A1, FGB and PAI-1 genes are associated with differences in myocardial perfusion.
    Satra M; Samara M; Wozniak G; Tzavara C; Kontos A; Valotassiou V; Vamvakopoulos NK; Tsougos I; Aleporou-Marinou V; Patrinos GP; Kollia P; Georgoulias P
    Pharmacogenomics; 2011 Feb; 12(2):195-203. PubMed ID: 21332313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endothelial dysfunction gene polymorphisms and the rate of liver fibrosis in chronic hepatitis C].
    Taratina OV; Krasnova TN; Samokhodskaia LM; Lopatkina TN; Tkachuk VA; Mukhina NA
    Ter Arkh; 2014; 86(4):45-51. PubMed ID: 24864467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
    Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
    Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1, factor V, factor II and methylenetetrahydrofolate reductase polymorphisms in women with recurrent miscarriage.
    Pietropolli A; Giuliani E; Bruno V; Patrizi L; Piccione E; Ticconi C
    J Obstet Gynaecol; 2014 Apr; 34(3):229-34. PubMed ID: 24484533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infection.
    Divella R; Mazzocca A; Gadaleta C; Simone G; Paradiso A; Quaranta M; Daniele A
    Cancer Genomics Proteomics; 2012; 9(4):193-8. PubMed ID: 22798504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment.
    Armendáriz-Borunda J; Rincón AR; Muñoz-Valle JF; Bueno-Topete M; Oregón-Romero E; Islas-Carbajal MC; Medina-Preciado D; González-García I; Bautista CA; García-Rocha S; Godoy J; Vázquez-Del Mercado M; Troyo-SanRoman R; Arellano-Olivera I; Lucano S; Alvarez-Rodríguez A; Salazar A
    J Investig Med; 2008 Oct; 56(7):944-53. PubMed ID: 18797412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in prothrombotic genes in young stroke patients in Greece: a case-controlled study.
    Ranellou K; Paraskeva A; Kyriazopoulos P; Batistatou A; Evangelou A; El-Aly M; Zis P; Tavernarakis A; Charalabopoulos K
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):430-5. PubMed ID: 25699610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy.
    Chen CH; Shu KH; Wen MC; Chen KJ; Cheng CH; Lian JD; Wu MJ; Yu TM; Tsai FJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3166-73. PubMed ID: 18495745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
    Nowakowska A
    Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
    Emingil G; Berdeli A; Gürkan A; Han Saygan B; Köse T; Atilla G
    J Clin Periodontol; 2007 Apr; 34(4):278-84. PubMed ID: 17257155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic variations in plasminogen activator inhibitor-1 gene and beta fibrinogen gene associated with glomerular microthrombosis in lupus nephritis and the gene dosage effect].
    Gong R; Liu Z; Chen Z; Li L
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):1-5. PubMed ID: 11836675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism.
    Oguzulgen IK; Yilmaz E; Demirtas S; Erkekol FO; Ekim N; Demir N; Numanoglu N; Ozel D; Ulu A; Akar N
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):73-7. PubMed ID: 18160588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of OAS1 Exon 7 rs10774671 Genetic Variation on Liver Fibrosis Progression in Egyptian HCV Genotype 4 Patients.
    Bader El Din NG; Anany MA; Dawood RM; Ibrahim MK; El-Shenawy R; El Abd YS; El Awady MK
    Viral Immunol; 2015 Nov; 28(9):509-16. PubMed ID: 26505957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasminogen activator inhibitor type 1 activity in women with unexplained very early recurrent pregnancy loss].
    Ivanov P; Komsa-Penkova R; Ivanov I; Konova E; Kovacheva K; Simeonova M; Tanchev S
    Akush Ginekol (Sofiia); 2010; 49(5):3-8. PubMed ID: 21268395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
    Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.